MedTrace Logo

A Study of Switching Avatrombopag and Rh-TPO in ITP

NCT04913597 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-06-04

No results posted yet for this study

Summary

Thrombopoietin receptor agonists (TPO-RAs) represent a highly effective and well-tolerated second-line ITP treatment that provides excellent responses.If there is cross-resistance between 2 drugs for the treatment of adult ITP is still unkonwn.The purpose of this study is to investigate the efficacy and safety of switching avatrombopag and rh-TPO in adults with ITP.

Conditions

  • Corticosteroid-resistant or Relapsed ITP

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Haixia Fu, MD · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-20
Primary Completion
2022-12-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913597 on ClinicalTrials.gov